The overall purpose of the Genomics/Endocrine/Statistics Core is to provide a common set of state-of-the-art biochemical and genetic analyses as well as statistical support to NCDDG researchers. The laboratories of the Core will provide assessments of hypothalamic-pituitary-adrenal axis and endocrine function, detailed genetic analyses and statistical support to the individual research projects of the NCDDG. Having these determinations performed by a central facility using a common set of assay modalities, common databases and statistical expertise will provide consistency across the 5 projects included in this 5 year study. Additionally, having a Core devoted to these analyses will guarantee high quality assay performance, allow for economies-of-scale in the purchase of assay reagents and technician time, and enable NCDDG investigators to more fully concentrate their efforts on the unique aspects of their particular project.
Mood and anxiety disorders are the most common of all psychiatric disorders and are associated with very significant morbidity and mortality. The primary goal of NCDDG Center is to accelerate the development of novel drugs for the treatment of depression and anxiety. The Genomics/Endocrine/Statistics Core will provide a common set of state-of-the-art biochemical and genetic analyses as well as statistical support to NCDDG researchers.
|Price, Matthew; Maples, Jessica L; Jovanovic, Tanja et al. (2015) An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. Depress Anxiety 32:392-9|
|Stehouwer, Jeffrey S; Birnbaum, Matthew S; Voll, Ronald J et al. (2015) Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor. Bioorg Med Chem 23:4286-302|
|Stehouwer, Jeffrey S; Goodman, Mark M (2015) Preparation of 1-Tosyloxy-4-Substituted-2-butenes Using Ag(I) Salts. Tetrahedron Lett 56:4480-4482|
|Ridgewell, Caitlin; Bray, Allison; Curtis, Kaylah et al. (2015) Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. J Neuropsychiatry Clin Neurosci 27:e170-1|
|Grillon, Christian; Hale, Elizabeth; Lieberman, Lynne et al. (2015) The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40:1064-71|
|Stehouwer, Jeffrey S; Bourke, Chase H; Owens, Michael J et al. (2015) Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) rec Bioorg Med Chem Lett 25:5111-4|
|Kilts, Clint D; Kennedy, Ashley; Elton, Amanda L et al. (2014) Individual differences in attentional bias associated with cocaine dependence are related to varying engagement of neural processing networks. Neuropsychopharmacology 39:1135-47|
|Dunlop, Boadie W; Rothbaum, Barbara O; Binder, Elisabeth B et al. (2014) Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials 15:240|
|Kaye, Joanna L; Dunlop, Boadie W; Iosifescu, Dan V et al. (2014) Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. J Psychiatr Res 57:51-7|
|Miller, Andrew H; Haroon, Ebrahim; Raison, Charles L et al. (2013) Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 30:297-306|
Showing the most recent 10 out of 48 publications